{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:00:08Z","timestamp":1791806408594,"version":"4.3.4"},"reference-count":53,"publisher":"BMJ","issue":"11","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30CA240139"],"award-info":[{"award-number":["P30CA240139"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA249949"],"award-info":[{"award-number":["R01CA249949"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA266528"],"award-info":[{"award-number":["R01CA266528"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Department of Veterans A\ufb00airs","award":["1IK6BX003787"],"award-info":[{"award-number":["1IK6BX003787"]}]},{"name":"Department of Veterans A\ufb00airs","award":["I01BX001179"],"award-info":[{"award-number":["I01BX001179"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2023,6,11]]},"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Gastric cancer (GC) ranks fifth in incidence and fourth for mortality worldwide. The response to immune checkpoint blockade (ICB) therapy in GC is heterogeneous due to tumour-intrinsic and acquired immunotherapy resistance. We developed an immunophenotype-based subtyping of human GC based on immune cells infiltration to develop a novel treatment option.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A algorithm was developed to reclassify GC into immune inflamed, excluded and desert subtypes. Bioinformatics, human and mouse GC cell lines, syngeneic murine gastric tumour model, and CTLA4 blockade were used to investigate the immunotherapeutic effects by restricting receptor tyrosine kinase (RTK) signalling in immune desert (ICB-resistant) type GC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our algorithm restratified subtypes of human GC in public databases and showed that immune desert-type and excluded-type tumours are ICB-resistant compared with immune-inflamed GC. Moreover, epithelial-mesenchymal transition (EMT) signalling was highly enriched in immune desert-type GC, and syngeneic murine tumours exhibiting mesenchymal-like, compared with epithelial-like, properties are T cell-excluded and resistant to CTLA4 blockade. Our analysis further identified a panel of RTKs as potential druggable targets in the immune desert-type GC. Dovitinib, an inhibitor of multiple RTKs, strikingly repressed EMT programming in mesenchymal-like immune desert syngeneic GC models. Dovitinib activated the tumour-intrinsic SNAI1\/2-IFN-\u03b3 signalling axis and impeded the EMT programme, converting immune desert-type tumours to immune inflamed-type tumours, sensitising these mesenchymal-like \u2018cold\u2019 tumours to CTLA4 blockade.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings identified potential druggable targets relevant to patient groups, especially for refractory immune desert-type\/ \u2018cold\u2019 GC. Dovitinib, an RTK inhibitor, sensitised desert-type immune-cold GC to CTLA4 blockade by restricting EMT and recruiting T cells.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/gutjnl-2022-329134","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T13:23:19Z","timestamp":1688476999000},"page":"2038-2050","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":36,"title":["Multivalent tyrosine kinase inhibition promotes T cell recruitment to immune-desert gastric cancers by restricting epithelial-mesenchymal transition via tumour-intrinsic IFN-\u03b3 signalling"],"prefix":"10.1136","volume":"72","author":[{"given":"Long Long","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Soutto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeem","family":"Bhat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dunfa","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Gomaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia Bin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian Wei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao Hui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiyo","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2869-1571","authenticated-orcid":false,"given":"Jashodeep","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nipun","family":"Merchant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Villarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9993-238X","authenticated-orcid":false,"given":"Alexander","family":"Zaika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0019-885X","authenticated-orcid":false,"given":"Chang Ming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5597-4588","authenticated-orcid":false,"given":"Wael","family":"El-Rifai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"key":"2024112221251644000_72.11.2038.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"key":"2024112221251644000_72.11.2038.2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"2024112221251644000_72.11.2038.3","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.1002\/cncr.30881","article-title":"Stomach cancer survival in the United States by race and stage (2001-2009): findings from the CONCORD-2 study","volume":"123 Suppl 24","author":"Jim","year":"2017","journal-title":"Cancer"},{"key":"2024112221251644000_72.11.2038.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"2024112221251644000_72.11.2038.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200690"},{"key":"2024112221251644000_72.11.2038.6","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad0095"},{"key":"2024112221251644000_72.11.2038.7","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S1470-2045(21)00097-8","article-title":"Ipilimumab alone or Ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study","volume":"22","author":"Pires da Silva","year":"2021","journal-title":"Lancet Oncol"},{"key":"2024112221251644000_72.11.2038.8","doi-asserted-by":"publisher","DOI":"10.1038\/nature13954"},{"key":"2024112221251644000_72.11.2038.9","doi-asserted-by":"publisher","DOI":"10.1038\/nature22079"},{"key":"2024112221251644000_72.11.2038.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1302369"},{"key":"2024112221251644000_72.11.2038.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"2024112221251644000_72.11.2038.12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"2024112221251644000_72.11.2038.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0349-y"},{"key":"2024112221251644000_72.11.2038.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"2024112221251644000_72.11.2038.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"2024112221251644000_72.11.2038.16","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1507"},{"key":"2024112221251644000_72.11.2038.17","doi-asserted-by":"publisher","DOI":"10.1038\/nature14404"},{"key":"2024112221251644000_72.11.2038.18","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20161950"},{"key":"2024112221251644000_72.11.2038.19","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0603"},{"key":"2024112221251644000_72.11.2038.20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1434"},{"key":"2024112221251644000_72.11.2038.21","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-3292"},{"key":"2024112221251644000_72.11.2038.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.06.028"},{"key":"2024112221251644000_72.11.2038.23","doi-asserted-by":"crossref","first-page":"9878","DOI":"10.3390\/ijms22189878","article-title":"Interplay of immunometabolism and epithelial-mesenchymal transition in the tumor microenvironment","volume":"22","author":"Chou","year":"2021","journal-title":"IJMS"},{"key":"2024112221251644000_72.11.2038.24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4459"},{"key":"2024112221251644000_72.11.2038.25","doi-asserted-by":"publisher","DOI":"10.1172\/JCI91190"},{"key":"2024112221251644000_72.11.2038.26","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201404208"},{"key":"2024112221251644000_72.11.2038.27","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0101-z"},{"key":"2024112221251644000_72.11.2038.28","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-4443"},{"key":"2024112221251644000_72.11.2038.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.09.028"},{"key":"2024112221251644000_72.11.2038.30","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.3762"},{"key":"2024112221251644000_72.11.2038.31","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-01841-2"},{"key":"2024112221251644000_72.11.2038.32","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13569"},{"key":"2024112221251644000_72.11.2038.33","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001358","article-title":"Deep Immunophenotyping at the single-cell level identifies a combination of anti-IL-17 and checkpoint blockade as an effective treatment in a preclinical model of data-guided personalized Immunotherapy","volume":"8","author":"Nagaoka","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2024112221251644000_72.11.2038.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.04.003"},{"key":"2024112221251644000_72.11.2038.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2021.01.010"},{"key":"2024112221251644000_72.11.2038.36","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10120-016-0667-4","article-title":"Examining the gastric cancer survival gap between Asians and whites in the United States","volume":"20","author":"Jin","year":"2017","journal-title":"Gastric Cancer"},{"key":"2024112221251644000_72.11.2038.37","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","article-title":"Assessment of pembrolizumab therapy for the treatment of microsatellite instability-high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials","volume":"7","author":"Chao","year":"2021","journal-title":"JAMA Oncol"},{"key":"2024112221251644000_72.11.2038.38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02105"},{"key":"2024112221251644000_72.11.2038.39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31257-1"},{"key":"2024112221251644000_72.11.2038.40","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/annonc\/mdy264","article-title":"Phase III, randomised trial of avelumab versus physician\u2019s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN gastric 300","volume":"29","author":"Bang","year":"2018","journal-title":"Ann Oncol"},{"key":"2024112221251644000_72.11.2038.41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-0025"},{"key":"2024112221251644000_72.11.2038.42","doi-asserted-by":"publisher","DOI":"10.1177\/1747493018778713"},{"key":"2024112221251644000_72.11.2038.43","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70030-0"},{"key":"2024112221251644000_72.11.2038.44","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3810"},{"key":"2024112221251644000_72.11.2038.45","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0356-4","article-title":"Targeting the TGFbeta pathway with Galunisertib, a TGFbetari small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade","volume":"6","author":"Holmgaard","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2024112221251644000_72.11.2038.46","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ccell.2021.12.009","article-title":"MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells","volume":"40","author":"Limagne","year":"2022","journal-title":"Cancer Cell"},{"key":"2024112221251644000_72.11.2038.47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0476-5"},{"key":"2024112221251644000_72.11.2038.48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2267"},{"key":"2024112221251644000_72.11.2038.49","doi-asserted-by":"publisher","DOI":"10.1016\/1074-7613(94)90087-6"},{"key":"2024112221251644000_72.11.2038.50","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028480","article-title":"Interferon \u03b3 and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity","volume":"11","author":"Alspach","year":"2019","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2024112221251644000_72.11.2038.51","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.13.7556"},{"key":"2024112221251644000_72.11.2038.52","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41577-021-00566-3","article-title":"Interferon-gamma: teammate or opponent in the tumour microenvironment?","volume":"22","author":"Gocher","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"2024112221251644000_72.11.2038.53","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01970","article-title":"Overview of the mechanisms that may contribute to the non-redundant activities of interferon-inducible CXC chemokine receptor 3 ligands","volume":"8","author":"Metzemaekers","year":"2017","journal-title":"Front Immunol"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2022-329134","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T00:26:48Z","timestamp":1732321608000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2022-329134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,4]]},"references-count":53,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,10,6]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1136\/gutjnl-2022-329134"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2022-329134","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,4]]}}}